Chain Pharmacy

Latest News


CME Content


The ACO Team

Pharmacists who collaborate with ACOs can find many ways to exercise their skills and expand their knowledge. Partnerships are popping up everywhere, and so are the opportunities.

Dr. Reddy’s Laboratories has launched moxifloxacin HCl tablets, 400 mg, a therapeutic equivalent generic version of Avelox on March 4, following FDA approval.

Pharmacy groups, representing more than 100,000 pharmacists in different pharmacy practice settings, have written to CMS Administrator Marilyn B. Tavenner to express their support for the expansion of medication therapy management (MTM) services to Medicare Part D beneficiaries in the CMS proposal released in early January.

FDA advisors decided against recommending over-the-counter (OTC) marketing approval of Primatene HFA inhaler (Armstrong Pharmaceuticals) for the temporary relief of mild symptoms of intermittent asthma in patients 12 years and older, at last week’s joint meeting of the FDA’s Nonprescription Drugs Advisory Committee and the Pulmonary-Allergy Drugs Advisory Committee.

The National Association of Chain Drug Stores has endorsed a congressional proposal to establish a workgroup to collaborate on solutions to reduce prescription drug abuse and without comprising access to medications.

Health Mart launched its 2014 Healthy Living Tour during the Independent Pharmacy Business Growth Conference in Orlando, Fla. Pharmacists and other healthcare professionals will visit more than 130 communities across the United States providing health education and free health screenings.

Actavis plans to purchase Forest Laboratories for approximately $25 billion in a cash and equity deal, creating a combination of “two of the world’s fastest growing specialty pharmaceutical companies, with combined annual revenues of more than $15 billion in 2015,” according to a Feb. 18 announcement.

A Christian pharmacist in Tennessee has filed a federal lawsuit against Walgreens claiming the chain fired him for refusing to sell the Plan B morning after pill.

Analysts expect to see key developments in categories that include cancer, heart failure, obesity and diabetes, and hepatitis C. They also look toward some greatly needed antibiotics to deploy in the war against superbugs.